Meirluc. Why stop your observations when people stop dying? If you do that, you are failing to capture people who go on living! OK so, median OS won't improve, but mean survival will go on improving. And OS48 and OS60 will beat earlier derived estimates but you won't be able to put any of that in your statistical analysis, because you have already unblinded. And then the longterm OS stats will become of academic interest only. (Except maybe to an HTA who might accept them.)
LP is not mistaken. There is an argument to keep this trial going and remaining blinded. But, there are several arguments to bring it to a close...
Personally, I'm not advocating one thing or the other, because I'm not in possession of as many facts as the company are. But if I was, it would probably be a difficult judgement call to make!
I also believe there will be another positive news on jan 23. The company needs to be very very careful since they are not unblind yet. But a positive news which don’t jeopardize the trials is what is needed. They know more than we are and if they want the pps go higher then better provide investor with better communications.
meirluc, I like Dan's question about why 46 months. It is not 4 yrs or not 3.5 yrs but just short of 2 months for 4 yrs. I see your response too taking the Data lock to June 2019 to reach that 46 months of the last dosage or so. I think it is a bit too far to wait till June 2019 for Data Lock. I am hoping to see Data Lock around March so as to meet submission deadlines to ASCO 2019 or some other venue sooner. I respect your knowledge and all the tireless hard work you do in analyzing interpreting and extrapolating the open data we got so far and I really appreciate it you share with us all these good things. A Big Thank You to you.